Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world

被引：0
|
作者：
Sugimoto, Chikatoshi
Inoue, Yoshikazu
Arai, Toru
Kasai, Takehiko
Akira, Masanori
Hayashi, Seiji
Tachibana, Kazunobu
Sasaki, Yumiko
Takeuchi, Naoko
Minomo, Syojiro
Ikegami, Naoya
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA4878
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4878
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study
    Kato, Motoyasu
    Miyamoto, Atsushi
    Izumi, Shinyu
    Inomata, Minoru
    Kamio, Koichiro
    Sumikawa, Hiromitsu
    Egashira, Ryoko
    Sugiura, Hiroaki
    Araya, Jun
    Takeuchi, Masahiro
    Takahashi, Kazuhisa
    Azuma, Arata
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [22] Evaluation of Extracellular Matrix Biomarkers in Response to Anti-Fibrotic Treatment of Idiopathic Pulmonary Fibrosis
    Jessen, H.
    Hoyer, N.
    Ronnow, S.
    Karsdal, M.
    Leeming, D. J.
    Sand, J. M.
    Shaker, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [23] A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
    Roach, Katy M.
    Sutcliffe, Amanda
    Matthews, Laura
    Elliott, Gill
    Newby, Chris
    Amrani, Yassine
    Bradding, Peter
    SCIENTIFIC REPORTS, 2018, 8
  • [24] A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
    Katy M. Roach
    Amanda Sutcliffe
    Laura Matthews
    Gill Elliott
    Chris Newby
    Yassine Amrani
    Peter Bradding
    Scientific Reports, 8
  • [25] Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
    Moor, Catharina
    Kimman, Merel L.
    van Manen, Mirjam J. G.
    Dirksen, Carmen D.
    Wijsenbeek, Marlies S.
    Van Jaarsveld, F. Xana
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [26] A review of Idiopathic Pulmonary Fibrosis patients on anti-fibrotic treatment in the mid west area
    Ryan, N.
    Ryan, P.
    Gleeson, E.
    Cullinan, M.
    Mcinerney, C.
    Casserly, B.
    O'Brien, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (SUPPL 10) : S441 - S442
  • [27] Pro-fibrotic Factors as Potential Biomarkers of Anti-fibrotic Drug Therapy in Patients With Idiopathic Pulmonary Fibrosis
    Lopez-Lopez, Lidia
    Cesar, Eva Cabrera
    Lara, Estrella
    Juan, M. Victoria Hidalgo-San
    Parrado, Concepcion
    Martin-Montanez, Elisa
    Garcia-Fernandez, Maria
    ARCHIVOS DE BRONCONEUMOLOGIA, 2021, 57 (03): : 231 - 233
  • [28] A Description Of Anti-Fibrotic Therapy Prescribing Preferences Amongst Pulmonary Practitioners For The Management Of Idiopathic Pulmonary Fibrosis
    Jablonski, R.
    Frogameni, A.
    Brown, K. K.
    Kamangar, N.
    Murgu, S.
    Raparia, K.
    Ryu, J.
    Raoof, S.
    Suh, R. D.
    Edell, E. S.
    Kamp, D. W.
    Raj, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [29] A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
    Shah, Parth, V
    Balani, Prachi
    Lopez, Angel R.
    Nobleza, Chelsea Mae N.
    Siddiqui, Mariah
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (01)
  • [30] Anti-Fibrotic Therapy for Idiopathic Pulmonary Fibrosis Is Associated with Decreased Mortality Among Hospitalized Patients
    Kelly, B.
    Thao, V.
    Dempsey, T. M.
    Sangaralingham, L.
    Payne, S.
    Limper, A. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345